Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

KMDA

K

Kamada Ltd. (KMDA)

NMS – Real vaqt narxi. Valyuta: USD

8.15

-0.07 (-0.85%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

8.36

+0.21 (2.58%)

Bozordan keyin: Mar 27, 2026, 5:13 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

REHOVOT, Israel and HOBOKEN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma's collection center in San Antonio, TX. The approval was obtained following an on-site inspection made by the FDA during February 2026.

Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript

Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript

Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript

Kamada (KMDA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Kamada (KMDA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Kamada (KMDA) Q4 Earnings and Revenues Miss Estimates

Kamada (KMDA) Q4 Earnings and Revenues Miss Estimates

Kamada (KMDA) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

REHOVOT, Israel, and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and full-year ended December 31, 2025.

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

Ahead of Kamada (KMDA) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Ahead of Kamada (KMDA) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Kamada (KMDA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

Videolar

No Data

There is no data to display

Press-relizlar

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

REHOVOT, Israel and HOBOKEN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma's collection center in San Antonio, TX. The approval was obtained following an on-site inspection made by the FDA during February 2026.

Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

REHOVOT, Israel, and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and full-year ended December 31, 2025.

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

REHOVOT, Israel, and HOBOKEN, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the Company has been awarded an extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four specialty plasma-derived products, WINRHO®, HEPAGAM®, CYTOGAM®, and VARIZIG®, for an additional two years. Valued at a range of $10-$14 million, the award secures ongoing sales of those products in the Canadian market between Q2-26 and Q1-28. The four commercial products are approved by Health Canada and the U.S. Food and Drug Administration (FDA). CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec.